- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2016
- Public Summary Document (PSD) November 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2016 PBAC Meeting - Word
Brentuximab vedotin (post-asct) – November 2016
Brentuximab vedotin (post-ASCT): Powder for I.V. infusion 50 mg; Adcetris®
Last updated
3 March 2017